Skandinaviska Enskilda Banken AB publ trimmed its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 44,689 shares of the biopharmaceutical company’s stock after selling 2,100 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in Regeneron Pharmaceuticals were worth $19,981,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. FMR LLC increased its holdings in Regeneron Pharmaceuticals by 6.3% during the second quarter. FMR LLC now owns 7,039,884 shares of the biopharmaceutical company’s stock worth $3,457,569,000 after buying an additional 416,192 shares during the last quarter. BlackRock Inc. increased its holdings in Regeneron Pharmaceuticals by 0.7% during the second quarter. BlackRock Inc. now owns 6,188,267 shares of the biopharmaceutical company’s stock worth $3,039,305,000 after buying an additional 41,406 shares during the last quarter. Vanguard Group Inc. increased its holdings in Regeneron Pharmaceuticals by 2.9% during the second quarter. Vanguard Group Inc. now owns 5,270,458 shares of the biopharmaceutical company’s stock worth $2,588,533,000 after buying an additional 148,962 shares during the last quarter. Harding Loevner LP increased its holdings in Regeneron Pharmaceuticals by 589.2% during the third quarter. Harding Loevner LP now owns 3,663,548 shares of the biopharmaceutical company’s stock worth $286,619,000 after buying an additional 3,131,966 shares during the last quarter. Finally, Artisan Partners Limited Partnership increased its holdings in Regeneron Pharmaceuticals by 1.5% during the second quarter. Artisan Partners Limited Partnership now owns 1,962,480 shares of the biopharmaceutical company’s stock worth $963,852,000 after buying an additional 29,252 shares during the last quarter. Institutional investors and hedge funds own 69.47% of the company’s stock.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) traded up $3.23 during midday trading on Friday, reaching $361.86. The company had a trading volume of 1,292,600 shares, compared to its average volume of 908,321. Regeneron Pharmaceuticals, Inc. has a 12-month low of $340.09 and a 12-month high of $543.55. The stock has a market cap of $38,540.00, a P/E ratio of 31.69, a P/E/G ratio of 1.44 and a beta of 1.56. The company has a quick ratio of 3.07, a current ratio of 3.63 and a debt-to-equity ratio of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share for the quarter, beating the consensus estimate of $3.83 by $0.16. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The firm had revenue of $1.50 billion during the quarter, compared to the consensus estimate of $1.45 billion. During the same period last year, the business posted $3.13 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 23.0% on a year-over-year basis. equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 13.55 earnings per share for the current year.

In related news, CFO Robert E. Landry sold 189 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total value of $94,700.34. Following the transaction, the chief financial officer now owns 10,099 shares in the company, valued at $5,060,204.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael S. Brown sold 1,500 shares of the firm’s stock in a transaction dated Thursday, October 5th. The shares were sold at an average price of $475.00, for a total value of $712,500.00. The disclosure for this sale can be found here. Insiders have sold 4,352 shares of company stock valued at $2,037,772 in the last three months. 10.80% of the stock is currently owned by company insiders.

A number of equities analysts have weighed in on the stock. Morgan Stanley reiterated an “equal weight” rating and set a $450.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 23rd. Canaccord Genuity reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, October 16th. Barclays lowered shares of Regeneron Pharmaceuticals from an “equal weight” rating to an “underweight” rating and cut their target price for the stock from $450.00 to $395.00 in a research report on Friday, October 20th. Oppenheimer reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, September 27th. Finally, Leerink Swann reiterated an “outperform” rating and set a $580.00 target price (up previously from $573.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $471.69.

ILLEGAL ACTIVITY NOTICE: “Skandinaviska Enskilda Banken AB publ Sells 2,100 Shares of Regeneron Pharmaceuticals, Inc. (REGN)” was published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/12/01/skandinaviska-enskilda-banken-ab-publ-sells-2100-shares-of-regeneron-pharmaceuticals-inc-regn.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.